Cell Therapeutics Inc., of Seattle, received a notice of allowance from the U.S. Patent and Trademark Office for the use of polyglutamate paclitaxel in combination with radiation for treating a variety of cancers.
Cepheid Inc., of Sunnyvale, Calif., was issued U.S. Patent No. 6,374,684 covering the fundamental fluidic control technology that enables cartridge-based automated preparation of biological samples in the company's GeneXpert detection system.
Esperion Therapeutics Inc., of Ann Arbor, Mich., was issued U.S. Patent No. 6,376,464 B1 covering compositions of matter related to apolipoprotein A-I agonist phospholipid complexes.
Genset SA, of Paris, was issued U.S. Patent No. 6,291,182 related to methods, algorithms and software for identifying regions of the genome that contain a gene associated with any detectable trait. Genset also said it received an allowance for a patent application relating to the g72 gene.
Immunicom Corp., of Huntingdon Valley, Pa., was issued U.S. Patent No. 6,365,362 covering methods and reagents for the rapid and efficient isolation of circulating cancer cells in human subjects.
Immunomedics Inc., of Morris Plains, N.J., was issued U.S. Patent No. 6,331,175 involving a method and kit for treating organs and tissues that are abnormal or misplaced.
Medicure Inc., of Winnipeg, Manitoba, was issued U.S. Patent No. 6,339,085 titled "Therapeutics for Cardiovascular and Related Diseases."
ZymoGenetics Inc., of Seattle, was issued U.S. Patent Nos. 5,989,866 and 6,352,971 covering composition of matter for both nucleic acid and protein sequences of the protein Zfgf5.